Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | VCAM1 | P19320 | 15/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.49 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5035917 | 0.85 | MAPK1 (0.55) | THRBALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL1625381 | 0.85 | VCAM1 (0.70) | THRBVCAM1ALDH1A1DNMT1DNMT3A | |
| SCHEMBL14677005 | 0.82 | THRB (0.71) | THRBVCAM1ALDH1A1KDM4EDNMT1 | |
| SCHEMBL5032646 | 0.80 | KDM4E (0.54) | THRBALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL6417364 | 0.77 | CA2 (0.56) | ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL18739951 | 0.77 | CA2 (0.61) | ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL686821 | 0.77 | VCAM1 (1.00) | THRBVCAM1ALDH1A1DNMT1DNMT3A | |
| SCHEMBL5035258 | 0.76 | ALDH1A1 (0.51) | THRBALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL6261490 | 0.76 | VCAM1 (1.00) | THRBVCAM1ALDH1A1KDM4E | |
| SCHEMBL1939366 | 0.75 | KDM4E (0.39) | THRBVCAM1ALDH1A1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378417-B2 | Pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1761541-B1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1761541-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123738-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | P2RX3, P2RX1, P2RX5 | THRB 1768/4885VCAM1 4699/4885ALDH1A1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.